Consistnet with our finding that energy metabolic-related gens were upregulated in subtype 2 breast cancer, compounds involving energy metabolism (such as PI3K inhibitor, mTOR inhibitor, NADH-ubiquinone oxidoreductase inhibitor, and ATP synthase inhibitor) were identified as potential therapeutic agents for subtype 2. The gene discussed is MTOR; the disease is breast cancer.